<DOC>
	<DOCNO>NCT00182312</DOCNO>
	<brief_summary>At least 5 every 1000 live-born baby premature weigh 500 1250 gram birth . Approximately 30-40 % high-risk infant either die survive lasting disability . The aim research reduce heavy burden illness . A multi-center randomized control trial design 2000 low birth weight infant enrol . Our goal determine whether avoidance methylxanthine drug improve survival without disability 18 month , correct prematurity . Methylxanthine drug caffeine use prevent treat periodic breathe breath-holding spell premature infant . However , strike lack evidence long-term efficacy safety therapy . Methylxanthines block naturally occur substance , call adenosine , protect brain episode oxygen deficiency . Such episodes common infant treat methylxanthines . It possible methylxanthines may worsen damage cause lack oxygen . Therefore , trial clarify whether methylxanthines cause good harm low birth weight infant .</brief_summary>
	<brief_title>Caffeine Apnea Prematurity ( CAP )</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Caffeine citrate</mesh_term>
	<criteria>birthweight 500 1250 gram postnatal age day 1 day 10 infant consider candidate methylxanthine therapy clinical staff dysmorphic feature congenital malformation adversely affect life expectancy neurodevelopment unlikely comply longterm followup prior treatment methylxanthine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Days</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>preterm infant</keyword>
	<keyword>low birthweight</keyword>
	<keyword>apnea prematurity</keyword>
	<keyword>methylxanthines</keyword>
	<keyword>developmental disability</keyword>
</DOC>